BioWorld Asia

Jan. 30, 2002

UroGene, Pierre Fabre Enter 3-Year Cancer Collaboration

PARIS UroGene SA entered into a three-year research collaboration with Pierre Fabre M dicament to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene. (BioWorld International) Read More

Symphogen Raises US$15M To Develop Polyclonal Antibodies

Peptide Study Yields Insights Into Autoimmune Disease Mechanisms

Synt:em, Baxter Collaborate On Peptide Mimetics Of MAbs

UK Creating Centers To Help Capitalize On Genetics Progress

Galapagos, Exelixis Collaborate To Analyze Functions Of Genes

Biogen Paying Schering $20M Or More Over MS Drug Patents

BIA Calls For More Support To Deal With Animal Rights Activists

Dutch Biotech Association Seeks Clearer Signals From Politicians

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...